Simulations Plus, Inc. (SLP): Price and Financial Metrics
SLP Stock Summary
- With a one year PEG ratio of 7,444.13, Simulations Plus Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.56% of US stocks.
- The price/operating cash flow metric for Simulations Plus Inc is higher than 94.57% of stocks in our set with a positive cash flow.
- The ratio of debt to operating expenses for Simulations Plus Inc is higher than it is for about merely 6.91% of US stocks.
- If you're looking for stocks that are quantitatively similar to Simulations Plus Inc, a group of peers worth examining would be IIN, SSTK, TRUE, OSIS, and ICUI.
- Visit SLP's SEC page to see the company's official filings. To visit the company's web site, go to www.simulations-plus.com.
SLP Stock Price Chart Interactive Chart >
SLP Price/Volume Stats
|Current price||$62.25||52-week high||$90.92|
|Prev. close||$66.14||52-week low||$26.00|
|Day high||$65.94||Avg. volume||217,429|
|50-day MA||$76.23||Dividend yield||0.36%|
|200-day MA||$65.48||Market Cap||1.24B|
Simulations Plus, Inc. (SLP) Company Bio
Simulations Plus develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The company was founded in 1996 and is based in Lancaster, California.
SLP Latest News Stream
|Loading, please wait...|
SLP Latest Social Stream
View Full SLP Social Stream
Latest SLP News From Around the Web
Below are the latest news stories about Simulations Plus Inc that investors may wish to consider to help them evaluate SLP as an investment opportunity.
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
Simulations Plus announced that its DILIsym division and the University of Pittsburgh Drug Discovery Institute jointly received a Phase I SBIR grant.
Shawn O'Connor became the CEO of Simulations Plus, Inc. ( NASDAQ:SLP ) in 2018, and we think it's a good time to look...
Simulations Plus (SLP) Presents At MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference - Slideshow
The following slide deck was published by Simulations Plus, Inc. in conjunction with this event....
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus will host fireside chat at BTIG's Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 18, at 12pm ET.
Simulations Plus, Inc. (NASDAQ: SLP) is a niche market leader with high-margin software and services (consulting) businesses in modelling and simulation for drug discovery and development. It has demonstrated a strong track record of execution via organic growth and accretive acquisition. This model has enabled it to generate free cash...
SLP Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|
Continue Researching SLPHere are a few links from around the web to help you further your research on Simulations Plus Inc's stock as an investment opportunity:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!